Novo Nordisk A/S global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

[출처/시간] Briefing.com - 6:01 AM ET, 05/26/2026

Co presented new results from the landmark POSEIDON real-world evidence study at the 94th European Atherosclerosis Society Congress in Athens, Greece. The study showed that CV inflammation remains highly prevalent among people with CVD despite current standard-of-care treatment. The study found that 2 in 5 people with ASCVD and CKD had CV inflammation, which is associated with an increased risk of major CV events.A second POSEIDON analysis recently published in the European Journal of Heart Failure showed that two in five people with heart failure also have CV inflammation1. In POSEIDON, CV inflammation was measured and defined by high-sensitivity C-reactive protein (hsCRP) levels =2 mg/L1. hsCRP is the most commonly used and widely available blood test for measuring CV inflammation4-6.
These findings underscore a significant gap in current CV care. Even when people receive guideline-recommended treatments to control, e.g., cholesterol, blood pressure and blood sugar, inflammation-driven CV risk persists3,7. The POSEIDON study represents one of the largest contemporary global assessments of CV inflammation prevalence in this high-risk population1,2."The POSEIDON study provides critical evidence that cardiovascular inflammation represents a significant source of persistent risk in people living with atherosclerotic cardiovascular disease and chronic kidney disease or heart failure, despite receiving standard of care treatment today," said Filip Knop, senior vice president and chief medical officer at Novo Nordisk. "Understanding the scope of cardiovascular inflammatory risk is essential, as we continue our innovation-driven research to develop a first-in-class therapy with the potential to address this critical unmet need."